We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.32 | 0.65% | 49.33 | 49.00 | 49.44 | 49.45 | 48.98 | 49.25 | 1,187,885 | 00:59:59 |
From May 2019 to May 2024
By Michael Dabaie
Sanofi (SNY) said sutimlimab met its primary efficacy endpoint in a Phase 3 trial for patients with cold agglutinin disease.
CAD is a severe and chronic rare blood disorder in which the immune system mistakenly attacks a person's own healthy red blood cells. There are currently no approved treatments, Sanofi said.
A total of 24 patients were enrolled; two withdrew from the study for non-drug related reasons. All 22 patients that completed Part A of the study have enrolled in an ongoing long-term follow-up study.
The primary efficacy outcome was response rate based on a composite of an increase in hemoglobin from baseline or reaching a hemoglobin level at treatment assessment endpoint and the absence of transfusions between weeks 5 to 26.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
November 21, 2019 10:10 ET (15:10 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
